- Home
- Who we are
- Read, watch, listen
- Pharmacy
- Home Delivery
- Specialty Pharmacy
- Specialty Pharmacy - Patients
- Care Specialists Program
- Education Center
- Hypercholesterolemia
- Solid organ transplant
- Asthma
- Cystic fibrosis
- Hemophilia
- Hepatitis C
- Human Immunodeficiency Virus (HIV)
- Inflammatory bowel disease
- Osteoporosis
- Multiple Sclerosis
- Oncology (cancer)
- Psoriasis and psoriatic arthritis
- Rheumatoid arthritis
- Rights and responsibilities
- Overcome medicine challenges
- Specialty Pharmacy - Providers
- Patient Forms
- Careers
- Benefits
- Hub + Home
- Medication Therapy Management Internship
- Managed Care Residency Program
- Application Process
- Contact Us
- Newsroom Custom Content
- Prime Careers Spotlight
- 2024
- Prime Careers Spotlight: September 2024
- Prime Careers Spotlight: October 2024
- Prime Careers Spotlight: November 2024
- 2025
- Prime Careers Spotlight: April 2025
- Prime Careers Spotlight: December 2025
- Prime Careers Spotlight: November 2025
- Prime Careers Spotlight: October 2025
- Prime Careers Spotlight: September 2025
- Prime Careers Spotlight: August 2025
- Prime Careers Spotlight: July 2025
- Prime Careers Spotlight: June 2025
- Prime Careers Spotlight: May 2025
- Prime Careers Spotlight: January 2026
- Prime Careers Spotlight: February 2026
- Publications
- Quarterly Pipeline
- 2024-2025
- Quarterly Drug Pipeline: July 2024
- Quarterly Drug Pipeline: April 2024
- Quarterly Drug Pipeline: January 2024
- Quarterly Drug Pipeline Template 2.0
- Quarterly Drug Pipeline: October 2024
- Quarterly Drug Pipeline: January 2025
- Quarterly Drug Pipeline: April 2025
- Quarterly Drug Pipeline: July 2025
- Quarterly Drug Pipeline: October 2025
- Quarterly Drug Pipeline: January 2026
- Clinical Highlights
- Clinical Highlights: September 2024
- Clinical Highlights: October 2024
- Clinical Highlights: November 2024
- Clinical Highlights: December 2024
- Clinical Highlights: January 2025
- Clinical Highlights: February 2025
- Clinical Highlights: March 2025
- Clinical Highlights: April 2025
- Drug Approvals
- Drug Approvals Monthly Update: August 2024
- Drug Approvals Monthly Update: June 2024
- Drug Approvals Monthly Update: May 2024
- Drug Approvals Monthly Update: April 2024
- Drug Approvals Monthly Update: March 2024
- Drug Approvals Monthly Update: February 2024
- Drug Approvals Monthly Update: January 2024
- Drug Approvals Quarterly Update
- Drug Approvals Monthly Update: September 2024
- Drug Approvals: October 2024
- Drug Approvals: November 2024
- Drug Approvals: December 2024
- Drug Approvals: January 2025
- Drug Approvals: July 2024
- Drug Approvals: February 2025
- Drug Approvals: March 2025
- Drug Approvals: April 2025
- Quarterly Drug Approvals
- 2024-2025
- Quarterly Drug Approvals: October 2024
- Quarterly Drug Approvals: January 2025
- Quarterly Drug Approvals: April 2025
- Quarterly Drug Approvals: July 2025
- Quarterly Drug Approvals: October 2025
- Quarterly Drug Approvals: January 2026
- High Cost Therapy Profile
- 2024-2025
- High-Cost Therapy Profile: August 2024
- High-Cost Therapy Profile: June 2024
- High-Cost Therapy Profile: May
- High-Cost Therapy Profile: April
- High-Cost Therapy Profile: March
- High-Cost Therapy Profile: February
- High-Cost Therapy Profile: January
- High-Cost Therapy Profile: September 2024
- HIGH COST THERAPY PROFILE: OCT 2024
- High Cost Therapy Profile: November 2024
- High Cost Therapy Profile: December 2024
- High Cost Therapy Profile: January 2025
- High Cost Therapy Profile: February 2025
- High-Cost Therapy Profile: March 2025
- High Cost Therapy Profile: April 2025
- High-Cost Therapy Profile: May 2025
- High-Cost Therapy Profile: June 2025
- High-Cost Therapy Profile: July 2025
- High-Cost Therapy Profile: August 2025
- High-Cost Therapy Profile: September 2025
- High-Cost Therapy Profile: October 2025
- High-Cost Therapy Profile: November 2025
- High-Cost Therapy Profile: December 2025
- High-Cost Therapy Profile: January 2026
- High-Cost Therapy Profile: February 2026
- High-Cost Therapy Profile: March 2026
- Oncology Insights
- 2024-2025
- Oncology Insights: Transformative treatment for small cell lung cancer
- Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
- Oncology Insights: October 2024
- Oncology Insights: December 2024
- Oncology Insights: 2024 Rewind
- Oncology Insights: February 2025
- Oncology Insights: March 2025
- Oncology Insights: April 2025
- Oncology Insights: May 2025
- Oncology Insights: June 2025
- Oncology Insights: July 2025
- Oncology Insights: August 2025
- Oncology Insights: September 2025
- Oncology Insights: October 2025
- Oncology Insights: November 2025
- Oncology Insights: December 2025
- Oncology Insights: January 2026
- Oncology Insights: February 2026
- Oncology Insights: March 2026
- FDA Decisions Expected
- 2024-2025
- FDA Decisions Expected: October 2024
- FDA Decisions Expected November 2024
- FDA Decisions Expected: December 2024
- FDA Decisions Expected: January 2025
- FDA Decisions Expected: February 2025
- FDA Decisions Expected: March 2025
- FDA Decisions Expected: April 2025
- FDA Decisions Expected: May 2025
- FDA Decisions Expected: June 2025
- FDA Decisions Expected: July 2025
- FDA Decisions Expected: August 2025
- FDA Decisions Expected: September2025
- FDA Decisions Expected: October 2025
- FDA Decisions Expected: November 2025
- FDA Decisions Expected: December 2025
- FDA Decisions Expected: January 2026
- FDA Decisions Expected: February 2026
- FDA Decisions Expected: March 2026
- Expert Clinical Network Insights
- 2024-2025
- Expert Clinical Network Insights: June 2024
- Expert Clinical Network Insights: April 2024
- Expert Clinical Network Insights: October 2024
- Expert Clinical Network Insights: December 2024
- Expert Clinical Network Insights: March 2025
- Expert Clinical Network Insights: August 2025
- Expert Clinical Network Insights: September 2025
- Expert Clinical Network Insights: December 2025
- Expert Clinical Network Insights: January 2026
- Prime Therapeutics Reports
- Fall 2024 Prime Therapeutics Report
- Spring 2024 Prime Therapeutics Report
- Summer 2024 Prime Therapeutics Report
- Spring 2025 Prime Therapeutics Report
- Summer 2025 Prime Therapeutics Report
- Fall 2025 Prime Therapeutics Report
- GLP-1
- 2024-2025
- GLP-1 Pipeline Update: November 2024
- GLP-1 Pipeline Update: November 2025
- The evolution of GLP-1s
- GLP-1 Pipeline Update: February 2025
- GLP-1 Pipeline Update: May 2025
- GLP-1 Pipeline Update: August 2025
- GLP-1 Pipeline Update: February 2026
- Clinical Insights
- 2022 Clinical Insights: Therapeutic Psychedlics: An emerging frontier in mental health
- 2022 Clinical Insights: Virtual reality: An emerging paradigm in healthcare
- Summer 2025 Issue: Clinical Insights – MASH
- Trending Topics & Drug Approvals
- 2024-2025
- Trending Topics & Drug Approvals: May 2025
- Trending Topics & Drug Approvals: June 2025
- Trending Topics & Drug Approvals: July 2025
- Trending Topics & Drug Approvals: August 2025
- Trending Topics & Drug Approvals: September 2025
- Trending Topics & Drug Approvals: November 2025
- Trending Topics & Drug Approvals: December 2025
- Trending Topics & Drug Approvals: January 2026
- Trending Topics & Drug Approvals: February 2026
- Cell & Gene Pipeline Outlook
- Clinical News
- Clinical News
- Clinical News: August 2024
- Clinical News: June 2024
- Clinical News: May 2024
- Clinical News: April 2024
- Employer Market Insight Reports
- Pharmacy Trend Reports
- Medicaid Pharmacy Trend Reports
- 2024 Medical Pharmacy Trend Report
- 2025 Medical Pharmacy Trend Report
- Weight management: A holistic journey
- Climate change: An imprint on health
- Virtual reality: An emerging paradigm in health care
- Research
- AMCP Nexus 2025 research posters
- AMCP Nexus 2024 Research Posters
- 2024 AMCP Annual Meeting Research Posters
- Media
- Compliance / Legal
- Home
- Who we are
- Read, watch, listen
- Pharmacy
- Home Delivery
- Specialty Pharmacy
- Specialty Pharmacy - Patients
- Care Specialists Program
- Education Center
- Hypercholesterolemia
- Solid organ transplant
- Asthma
- Cystic fibrosis
- Hemophilia
- Hepatitis C
- Human Immunodeficiency Virus (HIV)
- Inflammatory bowel disease
- Osteoporosis
- Multiple Sclerosis
- Oncology (cancer)
- Psoriasis and psoriatic arthritis
- Rheumatoid arthritis
- Rights and responsibilities
- Overcome medicine challenges
- Specialty Pharmacy - Providers
- Patient Forms
- Careers
- Benefits
- Hub + Home
- Medication Therapy Management Internship
- Managed Care Residency Program
- Application Process
- Contact Us
- Newsroom Custom Content
- Prime Careers Spotlight
- 2024
- Prime Careers Spotlight: September 2024
- Prime Careers Spotlight: October 2024
- Prime Careers Spotlight: November 2024
- 2025
- Prime Careers Spotlight: April 2025
- Prime Careers Spotlight: December 2025
- Prime Careers Spotlight: November 2025
- Prime Careers Spotlight: October 2025
- Prime Careers Spotlight: September 2025
- Prime Careers Spotlight: August 2025
- Prime Careers Spotlight: July 2025
- Prime Careers Spotlight: June 2025
- Prime Careers Spotlight: May 2025
- Prime Careers Spotlight: January 2026
- Prime Careers Spotlight: February 2026
- Publications
- Quarterly Pipeline
- 2024-2025
- Quarterly Drug Pipeline: July 2024
- Quarterly Drug Pipeline: April 2024
- Quarterly Drug Pipeline: January 2024
- Quarterly Drug Pipeline Template 2.0
- Quarterly Drug Pipeline: October 2024
- Quarterly Drug Pipeline: January 2025
- Quarterly Drug Pipeline: April 2025
- Quarterly Drug Pipeline: July 2025
- Quarterly Drug Pipeline: October 2025
- Quarterly Drug Pipeline: January 2026
- Clinical Highlights
- Clinical Highlights: September 2024
- Clinical Highlights: October 2024
- Clinical Highlights: November 2024
- Clinical Highlights: December 2024
- Clinical Highlights: January 2025
- Clinical Highlights: February 2025
- Clinical Highlights: March 2025
- Clinical Highlights: April 2025
- Drug Approvals
- Drug Approvals Monthly Update: August 2024
- Drug Approvals Monthly Update: June 2024
- Drug Approvals Monthly Update: May 2024
- Drug Approvals Monthly Update: April 2024
- Drug Approvals Monthly Update: March 2024
- Drug Approvals Monthly Update: February 2024
- Drug Approvals Monthly Update: January 2024
- Drug Approvals Quarterly Update
- Drug Approvals Monthly Update: September 2024
- Drug Approvals: October 2024
- Drug Approvals: November 2024
- Drug Approvals: December 2024
- Drug Approvals: January 2025
- Drug Approvals: July 2024
- Drug Approvals: February 2025
- Drug Approvals: March 2025
- Drug Approvals: April 2025
- Quarterly Drug Approvals
- 2024-2025
- Quarterly Drug Approvals: October 2024
- Quarterly Drug Approvals: January 2025
- Quarterly Drug Approvals: April 2025
- Quarterly Drug Approvals: July 2025
- Quarterly Drug Approvals: October 2025
- Quarterly Drug Approvals: January 2026
- High Cost Therapy Profile
- 2024-2025
- High-Cost Therapy Profile: August 2024
- High-Cost Therapy Profile: June 2024
- High-Cost Therapy Profile: May
- High-Cost Therapy Profile: April
- High-Cost Therapy Profile: March
- High-Cost Therapy Profile: February
- High-Cost Therapy Profile: January
- High-Cost Therapy Profile: September 2024
- HIGH COST THERAPY PROFILE: OCT 2024
- High Cost Therapy Profile: November 2024
- High Cost Therapy Profile: December 2024
- High Cost Therapy Profile: January 2025
- High Cost Therapy Profile: February 2025
- High-Cost Therapy Profile: March 2025
- High Cost Therapy Profile: April 2025
- High-Cost Therapy Profile: May 2025
- High-Cost Therapy Profile: June 2025
- High-Cost Therapy Profile: July 2025
- High-Cost Therapy Profile: August 2025
- High-Cost Therapy Profile: September 2025
- High-Cost Therapy Profile: October 2025
- High-Cost Therapy Profile: November 2025
- High-Cost Therapy Profile: December 2025
- High-Cost Therapy Profile: January 2026
- High-Cost Therapy Profile: February 2026
- High-Cost Therapy Profile: March 2026
- Oncology Insights
- 2024-2025
- Oncology Insights: Transformative treatment for small cell lung cancer
- Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
- Oncology Insights: October 2024
- Oncology Insights: December 2024
- Oncology Insights: 2024 Rewind
- Oncology Insights: February 2025
- Oncology Insights: March 2025
- Oncology Insights: April 2025
- Oncology Insights: May 2025
- Oncology Insights: June 2025
- Oncology Insights: July 2025
- Oncology Insights: August 2025
- Oncology Insights: September 2025
- Oncology Insights: October 2025
- Oncology Insights: November 2025
- Oncology Insights: December 2025
- Oncology Insights: January 2026
- Oncology Insights: February 2026
- Oncology Insights: March 2026
- FDA Decisions Expected
- 2024-2025
- FDA Decisions Expected: October 2024
- FDA Decisions Expected November 2024
- FDA Decisions Expected: December 2024
- FDA Decisions Expected: January 2025
- FDA Decisions Expected: February 2025
- FDA Decisions Expected: March 2025
- FDA Decisions Expected: April 2025
- FDA Decisions Expected: May 2025
- FDA Decisions Expected: June 2025
- FDA Decisions Expected: July 2025
- FDA Decisions Expected: August 2025
- FDA Decisions Expected: September2025
- FDA Decisions Expected: October 2025
- FDA Decisions Expected: November 2025
- FDA Decisions Expected: December 2025
- FDA Decisions Expected: January 2026
- FDA Decisions Expected: February 2026
- FDA Decisions Expected: March 2026
- Expert Clinical Network Insights
- 2024-2025
- Expert Clinical Network Insights: June 2024
- Expert Clinical Network Insights: April 2024
- Expert Clinical Network Insights: October 2024
- Expert Clinical Network Insights: December 2024
- Expert Clinical Network Insights: March 2025
- Expert Clinical Network Insights: August 2025
- Expert Clinical Network Insights: September 2025
- Expert Clinical Network Insights: December 2025
- Expert Clinical Network Insights: January 2026
- Prime Therapeutics Reports
- Fall 2024 Prime Therapeutics Report
- Spring 2024 Prime Therapeutics Report
- Summer 2024 Prime Therapeutics Report
- Spring 2025 Prime Therapeutics Report
- Summer 2025 Prime Therapeutics Report
- Fall 2025 Prime Therapeutics Report
- GLP-1
- 2024-2025
- GLP-1 Pipeline Update: November 2024
- GLP-1 Pipeline Update: November 2025
- The evolution of GLP-1s
- GLP-1 Pipeline Update: February 2025
- GLP-1 Pipeline Update: May 2025
- GLP-1 Pipeline Update: August 2025
- GLP-1 Pipeline Update: February 2026
- Clinical Insights
- 2022 Clinical Insights: Therapeutic Psychedlics: An emerging frontier in mental health
- 2022 Clinical Insights: Virtual reality: An emerging paradigm in healthcare
- Summer 2025 Issue: Clinical Insights – MASH
- Trending Topics & Drug Approvals
- 2024-2025
- Trending Topics & Drug Approvals: May 2025
- Trending Topics & Drug Approvals: June 2025
- Trending Topics & Drug Approvals: July 2025
- Trending Topics & Drug Approvals: August 2025
- Trending Topics & Drug Approvals: September 2025
- Trending Topics & Drug Approvals: November 2025
- Trending Topics & Drug Approvals: December 2025
- Trending Topics & Drug Approvals: January 2026
- Trending Topics & Drug Approvals: February 2026
- Cell & Gene Pipeline Outlook
- Clinical News
- Clinical News
- Clinical News: August 2024
- Clinical News: June 2024
- Clinical News: May 2024
- Clinical News: April 2024
- Employer Market Insight Reports
- Pharmacy Trend Reports
- Medicaid Pharmacy Trend Reports
- 2024 Medical Pharmacy Trend Report
- 2025 Medical Pharmacy Trend Report
- Weight management: A holistic journey
- Climate change: An imprint on health
- Virtual reality: An emerging paradigm in health care
- Research
- AMCP Nexus 2025 research posters
- AMCP Nexus 2024 Research Posters
- 2024 AMCP Annual Meeting Research Posters
- Media
- Compliance / Legal
-
Tap into our Expert Clinical Network Prime received a request for a nonformulary biologic in a young patient with severe Crohn’s disease, as the provider documented past failures of a biologic on...
-
Year 2 Prime Therapeutics’ leading research shows 1 in 12 remain on a GLP-1 drug for obesity at three years. Findings also show improved persistence with high-potency, obesity-approved GLP-1...
-
Reimagining pharmacy for our loved ones Please enter a valid video URL. The URL can point to any video file or a Youtube video. View playlist Please enter a valid video URL. The URL can point to...
-
Footnotes When we say we are different from our competition, we truly mean it. At Prime, we are driven by our purpose of providing the care we would want for our loved ones. Explore how we stay...
-
Ashley Block Week of Service is an annual event that allows our employees to come together to support our five charity partners, many of which address the major health care conditions we help our...
-
In this episode of "Beyond the Script," join Jami Snyder, Ann Walker and Tina Hawkins, PharmD to learn more about the need for states to closely manage physician administered drugs (PADs) and how...
-
Whitepaper Tab 1 Myth 1 Myth 2 Myth 3 Myth 4 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed nec ornare mi. Praesent ultrices ipsum eget est rutrum, eget congue orci molestie. Sed diam...
-
Senior Account Manager - Remote Investment Accountant, Principal - Remote Job description: The Senior Financial Application Analyst is responsible for the administration of the Hyperion application...
-
As prescription opioid overdoses rise in the U.S., the Prime/MRx Special Investigations Unit (SIU) shares how to identify if someone has overdosed and how you can help save a life
Prime Article: Perspectives -
Please enter a valid video URL. The URL can point to any video file or a Youtube video. Please enter a valid video URL. The URL can point to any video file or a Youtube video. Reimagine a PBM with...
-
Jessica Johnson, clinical consultant, shares how to identify and prevent opioid overdoses
Prime Article: Perspectives -
April 14, 2025 Author: Simone Ndujiuba, PharmD, BCOP In the United States, pancreatic cancer is the fourth leading cause of cancer related death.¹ In 2023, approximately 64,050 people were...
-
-
From cutting-edge system solutions to powerful stakeholder partnerships, the Medicaid Enterprise Systems Conference delivered key insights and connections that will shape health care modernization...
PA Sub-Categories: Specialty drugs Prime Article: Stories -
Clinical Solutions Vice President (Remote) Job description: The Medicare Part D pharmacy programs manager manages the coordination of benefits in the pharmacy program with Medicare Part D plans,...
-
Real-world, integrated data follows-up on previous insights, analytics.
PA Sub-Categories: GLP-1 Prime Article: Press Releases -
NCCN Recommendations for use of immunoglobulin² Intervention CAR T BsAbs Other indications Immunoglobulin replacement After CAR T-cell therapy, regular immune globulin infusions based on clinical...
-
High Cost Therapy Profile Eyebrow High-Cost Therapy Profile: February Detailed information about Marnetegragene autotemcel Intravenous (IV) Gene Therapy/Immunology Marnetegragene autotemcel...
-
FDA approved BiTEs: Brand name Generic name Route Target Indication First FDA indication approval date Blincyto Blinatumomab IV anti-CD19 / anti-CD3 Acute lymphocytic leukemia 12/3/2014 Columvi...
-
Edwards joins as president, markets.
Prime Article: Press Releases -
Designation demonstrates highest level of commitment to quality health care
Prime Article: Press Releases -
Designation demonstrates highest level of commitment to quality health care.
Prime Article: In the News -
Integrated support for patients with cystic fibrosis drives down cost, improves medication adherence
Prime’s IntegratedRx® – Cystic Fibrosis product earns 94% member satisfaction rate
PA Sub-Categories: Products Specialty drugs Prime Article: Stories -
Oral selective estrogen receptor degraders Agent Status and key trial data What to watch Elacestrant (Orserdu) Approved in 2023 as the first oral SERD in ESR1-mutant metastatic breast cancer via...
-
Clinical Solutions VP (Remote) Looking for your next career move and want to help Prime Therapeutics (Prime) put more care in health care? Check out the Prime Careers Spotlight, a monthly roundup...
-
Enhanced strategic consultation and new products like Medicare Predictive Model and Enrollment Capabilities are changing Prime’s government programs and delivering better access and costs to members
PA Sub-Categories: Products Technology Prime Article: Perspectives -
Tab 1 BEHAVIORAL HEALTH CORNER WEIGHT MANAGEMENT CORNER Clinical News EDITOR-IN-CHIEF: Maryam Tabatabai, PharmD EXECUTIVE EDITOR: Anna Schreck Bird, PharmD DEPUTY EDITORS: Erik Hamel, PharmD;...
-
Meredith Delk, senior vice president and general manager of state government solutions at Prime Therapeutics, shares more about the important role women play in our world today
PA Sub-Categories: Corporate responsibility Prime Article: Perspectives -
A Q&A with Kristen Tveit, SVP, chief financial officer, Magellan Rx
PA Sub-Categories: Corporate responsibility Prime Article: Perspectives -
Live updates from AMCP Annual Meeting
PA Sub-Categories: GLP-1 Specialty drugs Prime Article: Stories -
Drug name/Manufacturer/Dosage form retatrutide/Eli Lilly/SC Drug name/Manufacturer/Dosage form semaglutide (Wegovy)/Novo Nordisk/SC tirzepatide (Zepbound)/Eli Lilly/SC T2DM Access the complete...
-
AMCP Nexus offers opportunity to nurture next generation of managed care leaders
Prime Article: Stories -
The CDC is reporting influenza-like illness (ILI) for the week ending March 15, 2025 (week 11). Seasonal influenza activity remains increased across the U.S. but has decreased for five consecutive...
-
The content in this publication is not a substitute for professional medical advice. For questions regarding any medical condition or if you need medical advice, please contact your health care...
-
Maryam Tabatabai, PharmD, associate vice president of clinical information, shares more about how cell and gene therapies are transforming the treatment landscape, and how payers and providers can...
PA Sub-Categories: Specialty drugs Prime Article: Stories -
AIS Health
Prime Article: In the News -
cover image for summer 2025 New therapies, payer strategies and pipeline updates shaping the future of managed care Prime Therapeutics /summer-2025-prime-therapeutics-report The Prime Therapeutics...
Prime Article: Research & Publications PA Research & Publications: Prime Therapeutics Report -
Cover image for Summer 2024 Prime Therapeutics Report Pulmonary arterial hypertension: Exciting new approval and payer impact Prime Therapeutics /2024-summer-prime-therapeutics-report The Prime...
Prime Article: Research & Publications PA Research & Publications: Prime Therapeutics Report -
Event features Caitlin Berry, senior principal of public policy and government affairs at Prime Therapeutics
Prime Article: Events -
Ahead of her session with Andy Killpack, Liu — senior director of specialty clinical solutions at Prime/MRx — shares current care management strategies for cell and gene therapy and the future of...
Prime Article: Stories -
Researchers share insights on accelerated approvals, health equity in food allergies and legislative impacts on sight of service
PA Sub-Categories: GLP-1 Specialty drugs Technology Prime Article: Perspectives -
In this episode, our experts discuss Prime’s four primary tenets of practice for chronic weight management.
Prime Article: Stories -
Ahead of their session, Jacob and Timothy share how Prime/MRx is working alongside providers like Horizon Blue Cross Blue Shield of New Jersey to manage drug waste and rein in spend for specialty...
Prime Article: Stories -
Prime Therapeutics residents, Almina Gomez and Kathryn Makay, shared their research and experiences at annual managed care pharmacy event
PA Sub-Categories: Specialty drugs Prime Article: Perspectives -
One of the Prime Together Foundation’s 2023 grants went to TC Food Justice, which works to reduce food waste and hunger in the Twin Cities by linking those willing to help and those in need.
PA Sub-Categories: Corporate responsibility Prime Article: Perspectives -
Nathan Downhour, senior vice president of strategic pharmacy solutions, led the implementation of Prime’s innovative Advocate+ care model
PA Sub-Categories: Products Specialty drugs Prime Article: Stories -
New continuing education course showcases her expertise in biomarker testing and targeted therapy for EGFR-mutated NSCLC
Prime Article: Perspectives -
Certification recognizes quality service and continuous improvement
Prime Article: Press Releases -
Report features new highlights and rankings of the top 50 drug classes by percent of net spend.
PA Sub-Categories: Specialty drugs Prime Article: Press Releases -
-
In its annual fall report dedicated to oncology, Prime Therapeutics highlights strategies to improve outcomes, reduce costs and support patients — starting with a bold approach to managing cancer care
PA Sub-Categories: Specialty drugs Prime Article: Stories -
Prime is committed to simplifying the cancer care journey through leading oncology solutions designed to support people with cancer
Prime Article: Stories -
New report, an evolution of previous DEI reports, aims to demonstrate transparency and accountability for company’s corporate social responsibility journey
PA Sub-Categories: Corporate responsibility Prime Article: Stories -
Grant helps provide a home away from home for families facing cancer
PA Sub-Categories: Corporate responsibility Prime Article: Stories -
Payne to integrate communications, government affairs and policy efforts at leading purpose-driven, transparent PBM
Prime Article: Press Releases -
How Prime Therapeutics/Magellan Rx Management reimagines pharmacy to do what's right.
Prime Article: Perspectives -
-
Prime Therapeutics helps simplify the cancer care journey and manage drug costs through leading oncology solutions
PA Sub-Categories: Specialty drugs Prime Article: Stories -
At Pharmacy Benefit Management Institute (PBMI) annual conference, Prime received two awards: one for cost savings, another for leadership.
PA Sub-Categories: Awards Prime Article: Press Releases -